Next Phase Newsletter

An investment firm that manages innovative venture capital funds and is based in San Diego, California. The firm invests in early, growth, and expansion-stage technology and life science companies. The firm principally invests in early and growth-stage investments in Series A, B, and C preferred equity rounds with other top-tier institutional and corporate investors. The investment size is variable and dependent on the company’s capitalization plan and future capital requirements. The firm currently focuses its investment activities in parts of the western USA that are under-served by venture capital. The firm is actively seeking institutional investment limited partners and new investment opportunities. 
 
In the Life Sciences area, the firm seeks to invest in medical device, product, diagnostics, specialty pharma, and healthcare IT.  The firm is opportunistic in terms of sub-sectors and indications.  The firm generally seeks clinical stage therapeutics that are at least Phase II, and diagnostics and medical devices that are very close to or with FDA approval. 
 
The firm is led by a seasoned VC with a track record of investing.  The firm generally co-invests with other top-tier institutional and corporate investors, and will work with companies to help them organize an investment syndicate. The firm seeks investment opportunities in rapidly growing companies with world-class products and solutions that address major market needs; along with talented leadership, management teams, and boards with deep industry experience and track records of success. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global healthcare company that specializes in plasma-related medicines has a global presence in the US, Europe, and Asia. The firm’s external innovation arm seeks to partner with early-stage companies developing therapeutic assets that strategically align with the firm’s focus areas. The group is science-focused and strategically invests in the corporation’s long-term goal of developing pipelines in biotech beyond plasma-related medicines. The group primarily makes equity investments but is open to different structures such as co-development, licensing, and potentially acquisitions. The group often co-invests/syndicates with other investors and typically does not require a board seat. The group is open to considering global opportunities with a focus on the US and Europe. 

The group is focused on therapeutics and is not interested in diagnostics or other sectors. The group seeks strategic alignments within the parent company’s pharma business, which focuses on immunology, infectious diseases, pulmonology, and hematology. The group is particularly interested in biologics due to their expertise in this class of assets and is open to considering other classes of assets such as small molecules, cell and gene therapy (platform), mRNA therapies, etc. The group is also open to considering orphan diseases as well. In terms of phases of development, the group is interested in pre-clinical to early clinical phases. 

The group does not have any specific requirements for the company’s management team. The group acts as an active investor and is open to working with portfolio companies with their in-house expertise and leveraging the firm’s manufacturing capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A digital healthcare-focused seed fund that was founded in 2015 typically acts as the lead investor in a priced equity round. The firm’s team is made up of three partners and has collectively invested in more than a dozen digital health companies as individual investors. The fund currently focuses on opportunities across the United States, with a target investment in the $500,000 range. 

The firm seeks to fund companies working in the digital health space, including health data management systems, patient-physician interface, cloud computing, and software-enabled devices. 

The firm looks for teams that have some healthcare experience in senior management. The firm prefers a strong founding team, possessing varied skills that include technical expertise, sales, operational and marketing experience in senior leadership. After investment, the firm actively advise portfolio companies in various ways, including helping with introductions to health system customers, building teams and advising on operations and management. As such the firm will usually hold a seat on the board along with the founders. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A cross-border venture capital firm founded in 2014 and is headquartered in Tokyo, Japan, with USA offices in Cambridge, MA and Seattle, WA is currently investing from their second fund of $95M. Its LPs includes some of the largest Japanese pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies with the goal of bringing them to a more mature stage of development. Typically, the firm makes an initial investment ranging from under $1M to $3-6M dependent on the company’s stage of development. The firm can allocate up to $16M over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide. 

The firm only invests in therapeutics and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area. 

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the UK and founded in 2020 invests in women-led businesses in biosciences. The firm centers on a USD $100M fund raised as two rounds, the first having $30M to invest. The funds are focused health-tech ventures, with the main goal to hold investors and businesses accountable for diversity in management and teams. Check sizes can range between USD $350k-1.5M. The firm engages with companies in early stages and can also help identify ventures that they can back at a later stage. If the firm decides to not move forward with an investment, they are happy to support and utilize their global network to provide warm introductions to other investors and KOLs they have relationships with. The firm acts as a co-investor and will not lead. The firm is open to meeting companies based in the US, UK, Europe, Australia, and Asia. 

The firm does not invest in therapeutics and direct consumer marketing. The firm is interested in heavy sciences that have a technical element, including medical devices, diagnostics, and digital health. They may look at platforms that help identify therapeutics but will not look at pure therapeutics. The firm is indication-agnostic. The firm would like to see companies with a protectable IP. 

The firm does not require founders to be female, but require female management team members. The firm typically do not sit on board or observer seats but may if a company were to request. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A family office based in the US invests in pre-seed, seed and series A stage investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm may invest at later stages on a case-by-case basis. The firm invests across precision neuroscience, life sciences platforms, aerospace, digital deep tech, and climate tech. The firm prefers to invest in companies in conjunction with strong investment syndicate partners. The firm is open to opportunities worldwide. 
 
The firm’s life sciences funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds life science platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with main offices in China manages both RMB and USD funds. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm also manages innovation centers in China focusing on different special areas in Life Sciences and medical devices. With many years of operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe. The firm actively supports global companies to fast land China market by leveraging the fund’s connections with leading hospitals and KOLs in China. 
 
The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, AI, and Biotechnology R&D Services. The firm is opportunistic in terms of sub-sector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development. 
 
The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.